Adeno-associated virus-mediated microRNA delivery and therapeutics

Seminars in Liver Disease

Volumn 35, Issue 1, 2015, Pages 81-88

  Xie, Jun ^a   Burt, Daniel Robert ^a,b   Gao, Guangping ^a,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

adeno associated virus; in vivo gene delivery; microRNA inhibition; microRNA overexpression

Indexed keywords

MICRORNA; PARVOVIRUS VECTOR;

ARTICLE; CLINICAL TRIAL (TOPIC); DISEASES; FUNCTIONAL GENOMICS; GENE OVEREXPRESSION; HUMAN; IN VIVO GENE TRANSFER; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ANTAGONISTS AND INHIBITORS; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; PROCEDURES;

DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICRORNAS;

EID: 84925848922     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1397352     Document Type: Article

References (79)

1. Lewis B. P., Burge C. B., Bartel D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell: 2005; 120 1 15 20
2. Kim V. N. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol: 2005; 6 5 376 385
3. Cai X., Hagedorn C. H., Cullen B. R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA: 2004; 10 12 1957 1966
4. Borchert G. M., Lanier W., Davidson B. L. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol: 2006; 13 12 1097 1101
5. Lee R. C., Feinbaum R. L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell: 1993; 75 5 843 854
6. Calin G. A., Dumitru C. D., Shimizu M., et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A: 2002; 99 24 15524 15529
7. Calin G. A., Sevignani C., Dumitru C. D., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A: 2004; 101 9 2999 3004
8. Johnson S. M., Grosshans H., Shingara J., et al. RAS is regulated by the let-7 microRNA family. Cell: 2005; 120 5 635 647
9. Trang P., Medina P. P., Wiggins J. F., et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene: 2010; 29 11 1580 1587
10. Ji J., Shi J., Budhu A., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med: 2009; 361 15 1437 1447
11. Gao G. P., Alvira M. R., Wang L., Calcedo R., Johnston J., Wilson J. M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A: 2002; 99 18 11854 11859
12. Kota J., Chivukula R. R., O'Donnell K. A., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell: 2009; 137 6 1005 1017
13. van Rooij E., Sutherland L. B., Liu N., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A: 2006; 103 48 18255 18260
14. Thum T., Gross C., Fiedler J., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature: 2008; 456 7224 980 984
15. Montgomery R. L., Hullinger T. G., Semus H. M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation: 2011; 124 14 1537 1547
16. van Rooij E., Sutherland L. B., Qi X., Richardson J. A., Hill J., Olson E. N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science: 2007; 316 5824 575 579
17. Grueter C. E., van Rooij E., Johnson B. A., et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell: 2012; 149 3 671 683
18. Poy M. N., Hausser J., Trajkovski M., et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A: 2009; 106 14 5813 5818
19. Rayner K. J., Suárez Y., Dávalos A., et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science: 2010; 328 5985 1570 1573
20. Rayner K. J., Sheedy F. J., Esau C. C., et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest: 2011; 121 7 2921 2931
21. Rayner K. J., Esau C. C., Hussain F. N., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature: 2011; 478 7369 404 407
22. Chang J., Nicolas E., Marks D., et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol: 2004; 1 2 106 113
23. Jopling C. L., Yi M., Lancaster A. M., Lemon S. M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science: 2005; 309 5740 1577 1581
24. Li Y., Masaki T., Yamane D., McGivern D. R., Lemon S. M. Competing and noncompeting activities of miR-122 and the 5′ exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A: 2013; 110 5 1881 1886
25. Janssen H. L., Reesink H. W., Lawitz E. J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med: 2013; 368 18 1685 1694
26. Ventura A., Young A. G., Winslow M. M., et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell: 2008; 132 5 875 886
27. Kuhnert F., Mancuso M. R., Hampton J., et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development: 2008; 135 24 3989 3993
28. Esau C., Davis S., Murray S. F., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab: 2006; 3 2 87 98
29. Lanford R. E., Hildebrandt-Eriksen E. S., Petri A., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science: 2010; 327 5962 198 201
30. Elmén J., Lindow M., Schütz S., et al. LNA-mediated microRNA silencing in non-human primates. Nature: 2008; 452 7189 896 899
31. Ebert M. S., Neilson J. R., Sharp P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods: 2007; 4 9 721 726
32. Haraguchi T., Ozaki Y., Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res: 2009; 37 6 e43
33. Gentner B., Schira G., Giustacchini A., et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods: 2009; 6 1 63 66
34. Xie J., Ameres S. L., Friedline R., et al. Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods: 2012; 9 4 403 409
35. McCarty D. M., Ryan J. H., Zolotukhin S., Zhou X., Muzyczka N. Interaction of the adeno-associated virus Rep protein with a sequence within the A palindrome of the viral terminal repeat. J Virol: 1994; 68 8 4998 5006
36. Snyder R. O., Im D. S., Ni T., Xiao X., Samulski R. J., Muzyczka N. Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein. J Virol: 1993; 67 10 6096 6104
37. Dubielzig R., King J. A., Weger S., Kern A., Kleinschmidt J. A. Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. J Virol: 1999; 73 11 8989 8998
38. Kyöstiö S. R., Owens R. A., Weitzman M. D., Antoni B. A., Chejanovsky N., Carter B. J. Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels. J Virol: 1994; 68 5 2947 2957
39. Hoggan M. D., Blacklow N. R., Rowe W. P. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A: 1966; 55 6 1467 1474
40. Buller R. M., Janik J. E., Sebring E. D., Rose J. A. Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J Virol: 1981; 40 1 241 247
41. Rabinowitz J. E., Samulski R. J. Building a better vector: the manipulation of AAV virions. Virology: 2000; 278 2 301 308
42. Grieger J. C., Samulski R. J. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol: 2012; 507 229 254
43. Asokan A., Schaffer D. V., Samulski R. J. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther: 2012; 20 4 699 708
44. Mingozzi F., High K. A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet: 2011; 12 5 341 355
45. Büning H., Perabo L., Coutelle O., Quadt-Humme S., Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med: 2008; 10 7 717 733
46. Kotin R. M., Siniscalco M., Samulski R. J., et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A: 1990; 87 6 2211 2215
47. Samulski R. J., Zhu X., Xiao X., et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J: 1991; 10 12 3941 3950
48. Penaud-Budloo M., Le Guiner C., Nowrouzi A., et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol: 2008; 82 16 7875 7885
49. Li H., Malani N., Hamilton S. R., et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood: 2011; 117 12 3311 3319
50. Kaeppel C., Beattie S. G., Fronza R., et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med: 2013; 19 7 889 891
51. Zhong L., Malani N., Li M., et al. Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther: 2013; 24 5 520 525
52. Bryant L. M., Christopher D. M., Giles A. R., et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev: 2013; 24 2 55 64
53. Wang Z., Ma H. I., Li J., Sun L., Zhang J., Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther: 2003; 10 26 2105 2111
54. McCarty D. M., Fu H., Monahan P. E., Toulson C. E., Naik P., Samulski R. J. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther: 2003; 10 26 2112 2118
55. Kumar M. S., Erkeland S. J., Pester R. E., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A: 2008; 105 10 3903 3908
56. Soh J., Iqbal J., Queiroz J., Fernandez-Hernando C., Hussain M. M. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med: 2013; 19 7 892 900
57. Bak R. O., Hollensen A. K., Primo M. N., Sorensen C. D., Mikkelsen J. G. Potent microRNA suppression by RNA Pol II-transcribed 'Tough Decoy' inhibitors. RNA: 2013; 19 2 280 293
58. Xiao X., Li J., Samulski R. J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol: 1998; 72 3 2224 2232
59. Grieger J. C., Choi V. W., Samulski R. J. Production and characterization of adeno-associated viral vectors. Nat Protoc: 2006; 1 3 1412 1428
60. Gao G., Sena-Esteves M. Molecular Cloning: A Laboratory Manual Introducing Genes into Mammalian Cells: Viral Vectors. Vol. 2. New York Cold Spring Harbor Laboratory Press: 2012; 1209 1313
61. Zhang H., Yang B., Mu X., et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther: 2011; 19 8 1440 1448
62. Yang B., Li S., Wang H., et al. Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther: 2014; 22 7 1299 1309
63. Foust K. D., Nurre E., Montgomery C. L., Hernandez A., Chan C. M., Kaspar B. K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol: 2009; 27 1 59 65
64. Miyazaki Y., Adachi H., Katsuno M., et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med: 2012; 18 7 1136 1141
65. Hsu S. H., Wang B., Kota J., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest: 2012; 122 8 2871 2883
66. Tsai W. C., Hsu S. D., Hsu C. S., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest: 2012; 122 8 2884 2897
67. Dey B. K., Gagan J., Yan Z., Dutta A. miR-26a is required for skeletal muscle differentiation and regeneration in mice. Genes Dev: 2012; 26 19 2180 2191
68. van Rooij E., Olson E. N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov: 2012; 11 11 860 872
69. Kutay H., Bai S., Datta J., et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem: 2006; 99 3 671 678
70. Coulouarn C., Factor V. M., Andersen J. B., Durkin M. E., Thorgeirsson S. S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene: 2009; 28 40 3526 3536
71. Tsai W. C., Hsu P. W., Lai T. C., et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology: 2009; 49 5 1571 1582
72. Zhang J., Han C., Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology: 2012; 143 1 246 56.e8
73. Dahmani R., Just P. A., Perret C. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol: 2011; 35 11 709 713
74. Huse J. T., Brennan C., Hambardzumyan D., et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev: 2009; 23 11 1327 1337
75. Grimm D. The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence: 2011; 2 8
76. Grimm D., Streetz K. L., Jopling C. L., et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature: 2006; 441 7092 537 541
77. Grimm D., Wang L., Lee J. S., et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest: 2010; 120 9 3106 3119
78. Boudreau R. L., Martins I., Davidson B. L. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther: 2009; 17 1 169 175
79. McBride J. L., Boudreau R. L., Harper S. Q., et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A: 2008; 105 15 5868 5873